No Detail Found!

Effects of shikonin from fatty liver disease in rats Zicao on high-fat diet-induced nonalcoholic

Author(s)
Weijia Yang Department of Internal Medicine of Traditional Chinese Medicine, Zhejiang Hospital,Zhejiang,China
Minchun Yang Department of Internal Medicine of Traditional Chinese Medicine, Zhejiang Hospital,Zhejiang,China
Hui Yao Department of Internal Medicine of Traditional Chinese Medicine, Zhejiang Hospital,Zhejiang,China
Yelin Ma Department of Internal Medicine of Traditional Chinese Medicine, Zhejiang Hospital,Zhejiang,China
Xuanxuan Ren Department of Internal Medicine of Traditional Chinese Medicine, Zhejiang Hospital,Zhejiang,China
Long Teng Department of Internal Medicine of Traditional Chinese Medicine, Zhejiang Hospital,Zhejiang,China
Tao Wang Department of Internal Medicine of Traditional Chinese Medicine, Zhejiang Hospital,Zhejiang,China
Abstract
In this study, we aim to investigate whether shikonin prevents against NAFLD. After feeding high-fat diet (HFD) for 10 weeks, Sprague-Dawley rats were received different doses of shikonin (5mg/kg/day, 10mg/kg/day and 20mg/kg/day) by gavage for the last 12 weeks of a total of 22 weeks of a HFD. Our results showed that total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol, aspartate aminotransferase and alanine aminotransferase were significantly increased, while high-density lipoprotein cholesterol was decrease, accompanied by hepatic injury and lipid accumulation in HFD-fed rats. Shikonin treatment attenuated the above biochemical and histopathological changes. Similarly, HFD-induced the increase of hepatic TC and TG levels were also ameliorated by shikonin treatment. Furthermore, shikonin observably mitigated HFD-induced the liver fibrosis and the increase of plasminogen activator inhibitor type 1, connective tissue growth factor, collagen III and IV expression. Additionally, shikonin markedly inhibited HFD-induced the decrease of proliferator-activated receptor ? (PPAR?) and matrix metalloproteinases-9 (MMP-9) expression and the increase of tissue inhibitor of metalloproteinases-1 (TIMP-1) expression in liver tissue. This study demonstrates that shikonin ameliorates hepatic lipid dysregulation and fibrosis through PPAR? and MMP-9/TIMP1 axis, suggesting that shikonin may be a potential therapeutic agent for the treatment of NAFLD.
Publication Details
Page(s) 2527-2533
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: 6, Year: 2020

Request the full text from PASTIC

Keywords
Nonalcoholic fatty liver disease, Shikonin, liver injury, lipid accumulation, Fibrosis
0

Citations

0

Downloads

69

Views